Bruno Graziella, Merletti Franco, Biggeri Annibale, Bargero Giuseppe, Ferrero Stefania, Pagano Gianfranco, Cavallo Perin Paolo
Department of Internal Medicine, Turin University, Turin, Italy.
Diabetes Care. 2003 Jul;26(7):2150-5. doi: 10.2337/diacare.26.7.2150.
The first sign of diabetic nephropathy is microalbuminuria, but its predictive role of progression to overt nephropathy in type 2 diabetes has not yet been clarified. The aims of this study were to assess during 7 years of follow-up the incidence rate of overt nephropathy and the predictive role of microalbuminuria and other baseline variables (blood pressure, lipids, fibrinogen, uric acid, smoking, and HbA(1c) cumulative average during follow-up).
A prospective population-based study was performed in Casale Monferrato, Italy, including 1,253 type 2 diabetic patients recruited at baseline (1991-1992), 765 with normoalbuminuria (albumin excretion rate [AER] <20 microg/min) and 488 with microalbuminuria (AER 20-200 microg/min). All measurements were centralized. A nested case-control study within the cohort was performed, selecting four control subjects, frequency matched for age and attained individual time of follow-up with each case. Conditional regression analysis was performed to assess variables independently associated with risk of progression to overt nephropathy.
Of 1,253 total patients, 1,103 (88.0%) were included in the follow-up examination (median 5.33 years); their age and duration of disease at baseline were 68.4 +/- 10.5 years and 10.4 +/- 6.6 years, respectively. Cases of overt nephropathy were 202, giving an incidence rate of 37.0/1,000 person-years (95% CI 32.3-42.6). In conditional logistic regression analyses, microalbuminuria provided a 42% increased risk with respect to normoalbuminuria (95% CI 0.98-2.06), independently of duration of diabetes, hypertension, and systolic blood pressure. Other variables independently associated with progression to overt nephropathy were HbA(1c) cumulative average (P = 0.002), apolipoprotein B (P = 0.013), fibrinogen (P = 0.02), and HDL cholesterol (P = 0.03).
Of type 2 diabetic patients, 3.7% progress every year to overt nephropathy. Microalbuminuria is associated with a 42% increased risk of progression to overt nephropathy. Other independent predictors are HbA(1c), HDL cholesterol, apolipoprotein B, and fibrinogen.
糖尿病肾病的首个迹象是微量白蛋白尿,但其对2型糖尿病进展为显性肾病的预测作用尚未阐明。本研究的目的是在7年随访期间评估显性肾病的发病率以及微量白蛋白尿和其他基线变量(血压、血脂、纤维蛋白原、尿酸、吸烟以及随访期间HbA1c的累积平均值)的预测作用。
在意大利卡萨莱蒙费拉托进行了一项基于人群的前瞻性研究,纳入了1991 - 1992年基线时招募的1253例2型糖尿病患者,其中765例为正常白蛋白尿(白蛋白排泄率[AER]<20μg/min),488例为微量白蛋白尿(AER 20 - 200μg/min)。所有测量均集中进行。在队列中进行了一项巢式病例对照研究,为每个病例选择4名年龄和随访时间匹配的对照受试者。进行条件回归分析以评估与进展为显性肾病风险独立相关的变量。
1253例患者中,1103例(88.0%)纳入随访检查(中位随访时间5.33年);他们基线时的年龄和病程分别为68.4±10.5岁和10.4±6.6年。显性肾病病例为202例,发病率为37.0/1000人年(95%CI 32.3 - 42.6)。在条件逻辑回归分析中,与正常白蛋白尿相比,微量白蛋白尿使风险增加42%(95%CI 0.98 - 2.06),与糖尿病病程、高血压和收缩压无关。与进展为显性肾病独立相关的其他变量为HbA1c累积平均值(P = 0.002)、载脂蛋白B(P = 0.013)、纤维蛋白原(P = 0.02)和高密度脂蛋白胆固醇(P = 0.03)。
2型糖尿病患者中,每年有3.7%进展为显性肾病。微量白蛋白尿与进展为显性肾病的风险增加42%相关。其他独立预测因素为HbA1c、高密度脂蛋白胆固醇、载脂蛋白B和纤维蛋白原。